World’s First Antimicrobial and Antithrombogenic
Peripherally Inserted Central Catheter (PICC) Now Available in
Complete Portfolio of Single-, Double- and Triple-Lumen Formats and
WAYNE, Pa.--(BUSINESS WIRE)--Feb. 19, 2015--
Teleflex Incorporated (NYSE:TFX), a leading global provider of medical
devices for critical care and surgery, announced the launch of the
triple-lumen ARROW® PICC with Chlorag+ard®
Technology. This completes the Company’s portfolio of PICCs with the
unique and groundbreaking Chlorag+ard® Technology.
“With the completion of our ARROW® PICC with Chlorag+ard®
Technology portfolio, Teleflex can now help provide the benefits of
Chlorag+ard® Technology to all patients with PICCs, whether
they require a single-, double-, or triple-lumen device,” said Jay
White, President, Vascular Division of Teleflex. “Because ARROW®
PICCs with Chlorag+ard® Technology are both
antimicrobial and antithrombogenic, they provide an extra measure of
protection against thrombosis, occlusion, intimal hyperplasia and
infection. That is a crucial advantage at a time when many hospitals
still struggle to minimize these potentially deadly and costly
complications. Additionally, as house-wide reporting takes effect as
part of the Affordable Care Act in 2015, Chlorag+ard®
Technology’s proven ability to reduce PICC-related CLABSI will be
important for hospitals to consider.”
Pressure-injectable ARROW® PICCs with Chlorag+ard®
Technology are the world’s first FDA-cleared central venous catheters to
significantly reduce the risk of central line-associated bloodstream
infections (CLABSI) and PICC-related vessel thrombosis, compared to
traditional uncoated catheters.1 They are also the only PICCs
in the IV catheter marketplace that have received FDA 510(k) clearance
for both broad-spectrum antimicrobial and antithrombogenic protection.
Hospitals and clinicians have increasingly focused on reducing CLABSI
and catheter-related vessel thrombosis when inserting PICCs, which are
widely used in acute-care and long-term care settings. CLABSI is fatal
in 12%-25% of cases concerning critically ill patients without cancer
and 31%-36% of cases involving critically ill patients with cancer.2
PICC-related vessel thrombosis can lead to a CLABSI and also cause other
serious complications such as deep vein thrombosis (DVT) and pulmonary
In addition to CLABSI and thrombosis, the ARROW® PICC with
Chlorag+ard® Technology protects against
thrombotic, intraluminal catheter occlusion, the most common
non-infectious complication in the long-term use of central lines.4
Occlusions can delay patient therapy and also require the use of
expensive de-clotting agents.
Chlorag+ard® Technology uses a proprietary process
to chemically bond chlorhexidine to both the internal and external
surfaces of the catheter. The chlorhexidine-bonded surfaces, which
provide a controlled release of the broad-spectrum antimicrobial, are
the key to the PICC’s antimicrobial and antithrombogenic benefits.
Studies have shown that the risk of PICC-related infections is similar
to the widely recognized risk of bloodstream infections with central
venous catheters (CVCs). In fact, certain patient populations may be at
higher risk for PICC-related infections.5,6,7 Published rates
of PICC- associated symptomatic upper extremity vessel thrombosis vary
from 3.0% - 7.8%8,9, while asymptomatic rates are as high as
The impact of these complications on the healthcare economy is also
significant, with the average cost of care for upper extremity vessel
thrombosis exceeding $11,000 per incident11 and the cost of
care for CLABSIs exceeding $45,000 per incident.12
The ARROW® PICC with Chlorag+ard®
Technology has been the subject of two recently published studies that
documented substantial reduction in CLABSIs. Both studies appeared in
the Journal of the Association for Vascular Access (JAVA).13,14
The FDA clearance for ARROW® PICCs with Chlorag+ard®
Technology states that these IV catheters provide less thrombus
accumulation for at least 30 days. In Vitro data establishes that
the device provides 99.99% colonization reduction against gram + and
gram - bacteria and fungi for at least 30 days.15
Consideration of antimicrobial catheters is supported by multiple
regulatory and clinician organizations such as the Centers for Disease
Control and Epidemiology, the Society for Health Epidemiology of
America, and the Infusion Nurses Society. Their recommendations and
guidelines generally urge consideration of antimicrobial catheter usage
if the IV catheter is expected to dwell greater than five days and if,
after successful implementation of a comprehensive strategy to reduce
rates of CLABSI, the CLABSI rate is not decreasing.16,17
Additional information may be found at www.chloragard.com.
About Teleflex Incorporated
Teleflex is a leading global provider of specialty medical devices for a
range of procedures in critical care and surgery. Our mission is to
provide solutions that enable healthcare providers to improve outcomes
and enhance patient and provider safety. Headquartered in Wayne, PA,
Teleflex employs approximately 11,500 and serves healthcare providers
worldwide. Additional information about Teleflex can be obtained from
the company's website at teleflex.com.
Any statements contained in this press release that do not describe
historical facts may constitute forward-looking statements. Any
forward-looking statements contained herein are based on our
management's current beliefs and expectations, but are subject to a
number of risks, uncertainties and changes in circumstances, which may
cause actual results or company actions to differ materially from what
is expressed or implied by these statements. These risks and
uncertainties are identified and described in more detail in our filings
with the Securities and Exchange Commission, including our Annual Report
on Form 10-K.
Teleflex, Arrow, and Chorag+ard are
trademarks or registered trademarks of Teleflex Incorporated or its
© 2015 Teleflex Incorporated. All rights
Data on file using an intravascular ovine model.
Chopra V, Anand S, Krein SL, et al. Bloodstream infection, venous
thrombosis and peripherally inserted central catheters: reappraising
the evidence. Am J Med., 2012, 125(8):733-741.
Timsit JF, Misset B, Carlet J, et al. Central vein catheter-related
thrombosis in intensive care patients: incidence, risks factors, and
relationship with catheter-related sepsis. Chest, 1998,114:207-213.
McKnight S. Nurse's guide to understanding and treating thrombotic
occlusion of central vascular access devices. Medsurg Nurs, 2004,
Maki DG, Kluger DM, Crnich CJ. The risk of bloodstream infection in
adults with different intravascular devices: a systematic review of
200 published prospective studies. Mayo Clin Proc, 2006,
AJ, et al. Peripherally inserted central venous
catheter-associated bloodstream infections in hospitalized adult
patients. Infect Control Hosp Epidemiol, 2011, 32(2):125-130.
Donowitz GR, Maki DG, Crnich CJ et al. Infections in the neutropenic
patient — new views of an old problem. Hematology Am Soc Hematol Educ
Evans SR, Sharp JH, Lorraine LH, et al. Risk of symptomatic DVT
associated with peripherally inserted central catheters. Chest,
A, et al. Complications and cost associated with parenteral
nutrition delivered to hospitalized patients through either subclavian
or peripherally-inserted central catheters.
2000, 19(4): 237-243.
JV, et al. Incidence of upper limb venous thrombosis associated
with peripherally inserted central catheters (PICC). Br
J Radiol, 2005, 78(931):596-600.
Lissovoy G, Yusen
TE, et al. Cost for inpatient care of venous thrombosis: a trial
of enoxaparin vs standard heparin. Arch
Intern Med, 2000,160(20):3160-3165.
Zimlichman E, et al. Health Care–Associated Infections: A
Meta-analysis of Costs and Financial Impact on the US Health Care
System; JAMA Intern Med.2013;173(22):2039-2046.
Tavianini HD, Deacon V, Negrete J, et al. Up for the challenge:
eliminating peripherally inserted central catheter infections in a
complex patient population. J Vasc Access, 2014,19(3): 159–164.
Rutkoff GS. The influence of an antimicrobial peripherally inserted
central catheter on central line-associated bloodstream infections in
a hospital environment, J Vasc Access, 2014,19(3):172–179.
In vitro data on file, as compared to uncoated PICCs,
intravascular ovine model.
O'Grady NP, Alexander M, Burns LA, et al. Guidelines for the
prevention of intravascular catheter-related infections. Clin Infect
Dis, 2011, 52(9):e162–e193.
Infusion Nurses Society. Infusion nursing standards of practice. J
Infus Nurs. 2011, 34(1S): S1-S110.
Source: Teleflex Incorporated
Treasurer and Vice
President, Investor Relations